Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Financials
Key financial figures for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (Q1 2026), as reported in JPY.
Takeda Pharmaceutical Company Limited reported revenue of 1.22 trillion JPY for Q1 FY2026, up 10.2% from the same period a year earlier. Net income was 113.20 billion JPY, or 35.27 JPY per share. Operating margin came to 16.51%, against 16.68% a year earlier. Free cash flow for the period was 73.81 billion JPY. Across the last 5 reported quarters, quarterly revenue has risen from 1.11 trillion JPY in Q1 FY2025 to 1.22 trillion JPY in Q1 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Takeda Pharmaceutical Company Limited are on the SentiSense financials page.
- Revenue
- JPY 1.22T
- Net Income
- JPY 113.2B
- EPS
- JPY 35.83
- Total Assets
- JPY 15.66T
- Operating Cash Flow
- JPY 127.6B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q1 FY2026 | JPY 1.22T | JPY 113.2B | JPY 35.27 | 16.51% | JPY 73.8B |
| Q4 FY2025 | JPY 1.11T | -JPY 24.8B | -JPY 7.92 | 4.27% | JPY 10.1B |
| Q3 FY2025 | JPY 1.21T | JPY 105.5B | JPY 32.92 | 16% | JPY 150.9B |
| Q2 FY2025 | JPY 1.11T | -JPY 11.8B | -JPY 3.74 | 6.2% | JPY 325.4B |
| Q1 FY2025 | JPY 1.11T | JPY 124.2B | JPY 39.12 | 16.68% | JPY 140.4B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | JPY 4.78T | JPY 203.3B | JPY 63.91 | 11.99% | JPY 626.8B |
| FY2024 | JPY 4.58T | JPY 107.9B | JPY 33.62 | 7.48% | JPY 677.6B |
| FY2023 | JPY 4.26T | JPY 144.1B | JPY 45.58 | 5.02% | JPY 235.6B |
Frequently asked questions
What was Takeda Pharmaceutical Company Limited's revenue last quarter?
Takeda Pharmaceutical Company Limited reported revenue of 1.22 trillion JPY for Q1 FY2026, up 10.2% from the same period a year earlier.
Is Takeda Pharmaceutical Company Limited profitable?
Yes. Takeda Pharmaceutical Company Limited reported net income of 113.20 billion JPY for Q1 FY2026, a net margin of 9.28% on revenue.
How has Takeda Pharmaceutical Company Limited's margin trended?
Operating margin was 16.51% in Q1 FY2026, compared with 16.68% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Takeda Pharmaceutical Company Limited generate?
Takeda Pharmaceutical Company Limited generated free cash flow of 73.81 billion JPY in Q1 FY2026, after capital expenditure.
Figures are as reported by the filer in JPY and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) on SentiSense, with up to forty quarters and twenty fiscal years of history.